Tapasztalatok a levetiracetamkezeléssel gyermekkori epilepsziákban.

Translated title of the contribution: Experience with levetiracetam in childhood epilepsy

Magdolna Neuwirth, Judit Saracz, Márta Hegyi, Eva Paraicz, Katalin Kollár, Judit Móser, Beáta Rosdy, Agnes Herczegfalvi, A. Fogarasi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the efficacy and tolerability of levetiracetam in children with drug resistant epilepsy from a retrospective study. METHODS: We report the result of a study of 85 pediatric patients (mean 10.5 years, range: 1-24) with refractory generalized and focal epilepsy, who received levetiracetam as add-on treatment. The average duration of epilepsy was eight years, and the patient were treated with mean of 6.0 antiepileptic drugs before levetiracetam was introduced. RESULTS: Ten patients (12%) became seizure-free, three (3%) responded with seizure reduction of more than 90%, 32 (38%) responded with seizure reduction of more than 50% following introduction of levetiracetam. No response to levetiracetam was reported in 34% (n: 29). Positive psychotropic effect was observed in 26 patient (30%). Mild to moderate side effects were reported in 11 patients (13%), consisting most frequently general behavioral changes, aggression, sleep disturbances, but they ceased after decreasing the dose of levetiracetam. Mental retardation was associated with poor response and associated with more side effects. CONCLUSION: Levetiracetam is a well tolerated new antiepileptic drug that may effectively improve seizures control as an add-on drug in resistant epilepsy in childhood with good tolerability.

Original languageHungarian
Pages (from-to)179-182
Number of pages4
JournalIdeggyógyászati szemle
Volume59
Issue number5-6
Publication statusPublished - May 20 2006

Fingerprint

etiracetam
Epilepsy
Seizures
Anticonvulsants
Generalized Epilepsy
Partial Epilepsy
Aggression
Intellectual Disability

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neuwirth, M., Saracz, J., Hegyi, M., Paraicz, E., Kollár, K., Móser, J., ... Fogarasi, A. (2006). Tapasztalatok a levetiracetamkezeléssel gyermekkori epilepsziákban. Ideggyógyászati szemle, 59(5-6), 179-182.

Tapasztalatok a levetiracetamkezeléssel gyermekkori epilepsziákban. / Neuwirth, Magdolna; Saracz, Judit; Hegyi, Márta; Paraicz, Eva; Kollár, Katalin; Móser, Judit; Rosdy, Beáta; Herczegfalvi, Agnes; Fogarasi, A.

In: Ideggyógyászati szemle, Vol. 59, No. 5-6, 20.05.2006, p. 179-182.

Research output: Contribution to journalArticle

Neuwirth, M, Saracz, J, Hegyi, M, Paraicz, E, Kollár, K, Móser, J, Rosdy, B, Herczegfalvi, A & Fogarasi, A 2006, 'Tapasztalatok a levetiracetamkezeléssel gyermekkori epilepsziákban.', Ideggyógyászati szemle, vol. 59, no. 5-6, pp. 179-182.
Neuwirth M, Saracz J, Hegyi M, Paraicz E, Kollár K, Móser J et al. Tapasztalatok a levetiracetamkezeléssel gyermekkori epilepsziákban. Ideggyógyászati szemle. 2006 May 20;59(5-6):179-182.
Neuwirth, Magdolna ; Saracz, Judit ; Hegyi, Márta ; Paraicz, Eva ; Kollár, Katalin ; Móser, Judit ; Rosdy, Beáta ; Herczegfalvi, Agnes ; Fogarasi, A. / Tapasztalatok a levetiracetamkezeléssel gyermekkori epilepsziákban. In: Ideggyógyászati szemle. 2006 ; Vol. 59, No. 5-6. pp. 179-182.
@article{8c9eae339639415797a05c714bf59d1e,
title = "Tapasztalatok a levetiracetamkezel{\'e}ssel gyermekkori epilepszi{\'a}kban.",
abstract = "OBJECTIVE: To evaluate the efficacy and tolerability of levetiracetam in children with drug resistant epilepsy from a retrospective study. METHODS: We report the result of a study of 85 pediatric patients (mean 10.5 years, range: 1-24) with refractory generalized and focal epilepsy, who received levetiracetam as add-on treatment. The average duration of epilepsy was eight years, and the patient were treated with mean of 6.0 antiepileptic drugs before levetiracetam was introduced. RESULTS: Ten patients (12{\%}) became seizure-free, three (3{\%}) responded with seizure reduction of more than 90{\%}, 32 (38{\%}) responded with seizure reduction of more than 50{\%} following introduction of levetiracetam. No response to levetiracetam was reported in 34{\%} (n: 29). Positive psychotropic effect was observed in 26 patient (30{\%}). Mild to moderate side effects were reported in 11 patients (13{\%}), consisting most frequently general behavioral changes, aggression, sleep disturbances, but they ceased after decreasing the dose of levetiracetam. Mental retardation was associated with poor response and associated with more side effects. CONCLUSION: Levetiracetam is a well tolerated new antiepileptic drug that may effectively improve seizures control as an add-on drug in resistant epilepsy in childhood with good tolerability.",
author = "Magdolna Neuwirth and Judit Saracz and M{\'a}rta Hegyi and Eva Paraicz and Katalin Koll{\'a}r and Judit M{\'o}ser and Be{\'a}ta Rosdy and Agnes Herczegfalvi and A. Fogarasi",
year = "2006",
month = "5",
day = "20",
language = "Hungarian",
volume = "59",
pages = "179--182",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "5-6",

}

TY - JOUR

T1 - Tapasztalatok a levetiracetamkezeléssel gyermekkori epilepsziákban.

AU - Neuwirth, Magdolna

AU - Saracz, Judit

AU - Hegyi, Márta

AU - Paraicz, Eva

AU - Kollár, Katalin

AU - Móser, Judit

AU - Rosdy, Beáta

AU - Herczegfalvi, Agnes

AU - Fogarasi, A.

PY - 2006/5/20

Y1 - 2006/5/20

N2 - OBJECTIVE: To evaluate the efficacy and tolerability of levetiracetam in children with drug resistant epilepsy from a retrospective study. METHODS: We report the result of a study of 85 pediatric patients (mean 10.5 years, range: 1-24) with refractory generalized and focal epilepsy, who received levetiracetam as add-on treatment. The average duration of epilepsy was eight years, and the patient were treated with mean of 6.0 antiepileptic drugs before levetiracetam was introduced. RESULTS: Ten patients (12%) became seizure-free, three (3%) responded with seizure reduction of more than 90%, 32 (38%) responded with seizure reduction of more than 50% following introduction of levetiracetam. No response to levetiracetam was reported in 34% (n: 29). Positive psychotropic effect was observed in 26 patient (30%). Mild to moderate side effects were reported in 11 patients (13%), consisting most frequently general behavioral changes, aggression, sleep disturbances, but they ceased after decreasing the dose of levetiracetam. Mental retardation was associated with poor response and associated with more side effects. CONCLUSION: Levetiracetam is a well tolerated new antiepileptic drug that may effectively improve seizures control as an add-on drug in resistant epilepsy in childhood with good tolerability.

AB - OBJECTIVE: To evaluate the efficacy and tolerability of levetiracetam in children with drug resistant epilepsy from a retrospective study. METHODS: We report the result of a study of 85 pediatric patients (mean 10.5 years, range: 1-24) with refractory generalized and focal epilepsy, who received levetiracetam as add-on treatment. The average duration of epilepsy was eight years, and the patient were treated with mean of 6.0 antiepileptic drugs before levetiracetam was introduced. RESULTS: Ten patients (12%) became seizure-free, three (3%) responded with seizure reduction of more than 90%, 32 (38%) responded with seizure reduction of more than 50% following introduction of levetiracetam. No response to levetiracetam was reported in 34% (n: 29). Positive psychotropic effect was observed in 26 patient (30%). Mild to moderate side effects were reported in 11 patients (13%), consisting most frequently general behavioral changes, aggression, sleep disturbances, but they ceased after decreasing the dose of levetiracetam. Mental retardation was associated with poor response and associated with more side effects. CONCLUSION: Levetiracetam is a well tolerated new antiepileptic drug that may effectively improve seizures control as an add-on drug in resistant epilepsy in childhood with good tolerability.

UR - http://www.scopus.com/inward/record.url?scp=33747424753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747424753&partnerID=8YFLogxK

M3 - Article

C2 - 16786712

AN - SCOPUS:33747424753

VL - 59

SP - 179

EP - 182

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 5-6

ER -